Table 1. Patient information.

Cohort	300 patients with MSP analyisis	158 patients with BGS analysis
Gender
Male	201 (67.00%)	112 (70.89%)
Female	99 (33.00%)	46 (29.11%)
Age at surgery
≤ 60	181 (60.33%)	90 (56.96%)
> 60	119 (39.67%)	68 (43.04%)
Tumor size
< 4.0	39 (13.00%)	27 (17.09%)
≥ 4.0	261 (87.00%)	131 (82.81%)
Tumor location
Upper third	69 (23.00%)	43 (27.21%)
Middle third	81 (27.00%)	36 (22.78%)
Lower third	131 (43.67%)	71 (44.94%)
More than 2/3 stomach	19 (6.33%)	8 (5.06%)
Depth of tumor invasion (T stage)
T1	3 (1.00%)	2 (1.27%)
T2	28 (9.33%)	19 (12.03%)
T3	185 (61.67%)	98 (62.02%)
T4	84 (28.00%)	39 (24.68%)
Number of metastatic lymph nodes (N stage)
N0	80 (26.67%)	31 (19.62%)
N1	105 (35.00%)	57 (36.08%)
N2	64 (21.33%)	43 (27.22%)
N3	51 (17.00%)	27 (17.08%)
Location of lymph node metastasis
No	80 (26.67%)	31 (19.62%)
Perigastric	95 (31.67%)	63 (39.87%)
Extragastric	125 (41.66%)	64 (40.51%)
Lauren classification
Intestinal	82 (27.33%)	40 (25.32%)
Diffuse	211 (70.33%)	107 (67.72%)
Mixed	7 (2.34%)	11 (6.96%)
ZNF545 promoter methylation (MSP)
Hypermethylation	72 (24.00%)	–
Hypomethylation	61 (20.33)	–
Non-methylation	167 (55.67%)	–
Methylated CpG site count (BGS)
2 or less	–	76 (48.10%)
3 or more	–	82 (51.90%)
Methylated status of CpG −232 (BGS)
Unmethylated	–	94 (59.49%)
Methylated	–	64 (40.51%)
Methylated status of CpG −214 (BGS)
Unmethylated	–	84 (53.16%)
Methylated	–	74 (46.84%)
Methylated status of CpG −176 (BGS)
Unmethylated	–	86 (54.43%)
Methylated	–	72 (45.57%)
Methylated status of CpG −144 (BGS)
Unmethylated	–	86 (54.43%)
Methylated	–	72 (45.57%)
Methylated status of CpG −116 (BGS)
Unmethylated	–	96 (60.76%)
Methylated	–	62 (39.24%)